Thrombocytosis and Thrombosis: Is There Really a Correlation?

Abstract

Purpose of Review

Thrombocytosis is common to all myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis. Despite the traditionally held belief amongst many clinicians that thrombocytosis correlates with thrombosis risk, there is little evidence in the literature to support that claim. Herein we critically analyze the literature to better understand the relationship between thrombocytosis and risk of thrombosis in MPN.

Recent Findings

Both retrospective and prospective studies argue against associations between thrombocytosis and risk of thrombosis in patients with ET and PV. Rather, most studies suggest that the presence of extreme thrombocytosis is instead associated with an increased risk of hemorrhagic events, a paradoxical phenomenon with important clinical implications.

Summary

Thrombosis risk has a multifactorial set of etiologies in MPNs. While qualitative abnormalities of the platelets may contribute, associations between platelet quantity and thrombosis risk are weak in MPN patients.

This is a preview of subscription content, access via your institution.

Fig. 1

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med. 2003;139(6):470–5.

    PubMed  Google Scholar 

  2. 2.

    Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245(3):295–300.

    CAS  PubMed  Google Scholar 

  3. 3.

    Varghese LN, et al. The thrombopoietin receptor: structural basis of traffic and activation by ligand, mutations, agonists, and mutated calreticulin. Front Endocrinol (Lausanne). 2017;8:59.

    Google Scholar 

  4. 4.

    Vannucchi AM, Barbui T. Thrombocytosis and thrombosis. Hematology Am Soc Hematol Educ Program. 2007;2007:363–70.

    Google Scholar 

  5. 5.

    Skoda RC, Duek A, Grisouard J. Pathogenesis of myeloproliferative neoplasms. Exp Hematol. 2015;43(8):599–608.

    CAS  PubMed  Google Scholar 

  6. 6.

    James C, Ugo V, le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8.

    CAS  PubMed  Google Scholar 

  7. 7.

    Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–6.

    CAS  PubMed  Google Scholar 

  8. 8.

    Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.

    PubMed  PubMed Central  Google Scholar 

  9. 9.

    Zoi K, Cross NCP. Genomics of myeloproliferative neoplasms. J Clin Oncol. 2017;35(9):947–54.

    CAS  PubMed  Google Scholar 

  10. 10.

    ••Barbui T, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-33; quiz 5252. Practice-changing publication validating IPSET-thrombosis score for risk-stratifying patients with ET into three categories based on thrombotic risk.

  11. 11.

    Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.

    PubMed  PubMed Central  Google Scholar 

  12. 12.

    Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8(3):556–62.

    CAS  PubMed  Google Scholar 

  13. 13.

    Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer. 1991;67(11):2926–30.

    CAS  PubMed  Google Scholar 

  14. 14.

    Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R, et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer. 1986;58(11):2440–7.

    CAS  PubMed  Google Scholar 

  15. 15.

    Campbell PJ, MacLean C, Beer PA, Buck G, Wheatley K, Kiladjian JJ, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(7):1409–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Harrison CN. Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial. Semin Thromb Hemost. 2006;32(3):283–8.

    PubMed  Google Scholar 

  17. 17.

    Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–9.

    CAS  PubMed  Google Scholar 

  18. 18.

    ••Barbui T, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369 Practice-changing revision of well-established IPSET-thrombosis score used for thrombotic risk stratification in patients with ET.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    ••Haider M, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016;91(4):390–4 External validation for revised IPSET-thrombosis score for patients with ET which is currently used in clinical practice.

    PubMed  Google Scholar 

  20. 20.

    •Gugliotta L, et al. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2016;46:18–25 Large cohort study assessing thrombotic risk factors, including platelet count, amongst Ph negative MPNs.

    PubMed  Google Scholar 

  21. 21.

    Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010;116(7):1051–5.

    CAS  PubMed  Google Scholar 

  22. 22.

    Hernandez-Boluda JC, et al. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Ann Hematol. 2013;92(6):771–5.

    CAS  PubMed  Google Scholar 

  23. 23.

    Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272–90.

    CAS  PubMed  Google Scholar 

  24. 24.

    Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006;107(11):4214–22.

    CAS  PubMed  Google Scholar 

  25. 25.

    Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132–43.

    CAS  PubMed  Google Scholar 

  26. 26.

    Di Nisio M, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249–59.

    PubMed  Google Scholar 

  27. 27.

    Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348–58.

    PubMed  Google Scholar 

  28. 28.

    Alvarez-Larran A, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363–9.

    CAS  PubMed  Google Scholar 

  29. 29.

    Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.

    CAS  PubMed  Google Scholar 

  30. 30.

    Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82.

    CAS  PubMed  Google Scholar 

  31. 31.

    Cervantes F, Alvarez-Larrán A, Arellano-Rodrigo E, Granell M, Domingo A, Montserrat E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia. 2006;20(1):55–60.

    CAS  PubMed  Google Scholar 

  32. 32.

    Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95(10):1788–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Müllauer L, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol. 2012;87(7):669–72.

    PubMed  Google Scholar 

  34. 34.

    Barosi G, Rosti V, Bonetti E, Campanelli R, Carolei A, Catarsi P, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One. 2012;7(4):e35631.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Kc D, Falchi L, Verstovsek S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol. 2017;96(10):1595–604.

    PubMed  Google Scholar 

  36. 36.

    Guglielmelli P, Carobbio A, Rumi E, de Stefano V, Mannelli L, Mannelli F, et al. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer J. 2020;10(2):21.

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(4):716–9.

    CAS  PubMed  Google Scholar 

  38. 38.

    Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92(1):94–108.

    CAS  PubMed  Google Scholar 

  39. 39.

    Koren-Michowitz M, Lavi N, Ellis MH, Vannucchi AM, Mesa R, Harrison CN. Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. Ann Hematol. 2017;96(1):87–92.

    PubMed  Google Scholar 

  40. 40.

    •Chu DK, et al. Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review. Ann Intern Med. 2017;167(3):170–80 A recent meta-analysis suggesting unclear net benefit of antiplatelet therapy in patients with ET.

    PubMed  Google Scholar 

  41. 41.

    Alvarez-Larran A, Pereira A, Guglielmelli P, Hernandez-Boluda JC, Arellano-Rodrigo E, Ferrer-Marin F, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101(8):926–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Larsen ML, Pedersen OH, Hvas AM, Niekerk PBK, Bønløkke S, Kristensen SD, et al. Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. Platelets. 2019;30(3):322–8.

    CAS  PubMed  Google Scholar 

  43. 43.

    •Roccsa B, et al. A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood. 2020; https://doi.org/10.1182/blood.2019004596. Important recent randomized study evaluating efficacy of different aspirin regimens in patients with ET.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Brady L. Stein.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Myeloproliferative Neoplasms

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Galvez, C., Stein, B.L. Thrombocytosis and Thrombosis: Is There Really a Correlation?. Curr Hematol Malig Rep 15, 261–267 (2020). https://doi.org/10.1007/s11899-020-00588-z

Download citation

Keywords

  • Thrombocytosis
  • Thrombosis
  • Myeloproliferative neoplasms
  • Essential thrombocythemia
  • Polycythemia vera